Abstract Library

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,

#3730 Somatostatin receptor expression in lung neuroendocrine tumors – An analysis of Dotatate PET scans

Introduction: Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine (carcinoid) tumors has not been well-characterized using modern positron emission tomography (PET) imaging. Understanding the degree and uniformity of SSTR expression is important to establish the role of SSTR-targeted treatments, including peptide receptor radiotherapy (PRRT), in lung NETs.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Montilla-Soler J, El-Haddad G, Strosberg J,

Keywords: PET dotatate, cu64, ga68, lung NET, SSTR Positive,

#1508 NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results

Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Strosberg J

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: Lutathera, PRRT, NET,

#517 Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstr) Expressing Organ and Tumor

Introduction: Since Ga68 DOTATATE has a high affinity to only sstr2 but no affinity to sstr3 and sstr5, Ga68 DOTANOC has been suggested to be a better radioligand with higher affinity to sstr3 and sstr5 and high affinity to sstr2, as well.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Demirci E, Kabasakal L, Ocak M, Aygun A, Ozcan R,

Keywords: Octreotide PET,